Helsinki

• A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM … Ended recruitment
  2024-517417-32-00 4 2018-11-22 CHRONIC MYELOID LEUKEMIA
• Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in pati … Ended recruitment
  2023-508551-40-00 6 2018-06-08 Coronary artery multi-vessel disease and left main stenosis
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended recruitment
  2023-504802-12-00 7 2018-05-16 Lymphoma of B-cell origin
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended recruitment
  2024-514275-18-00 10 2017-12-06 Mantle Cell Lymphoma (MCL)
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• DupuytrEn Treatment EffeCtiveness Trial (DETECT) Ended recruitment
  2024-515110-40-00 5 2017-09-15 Dupuytren's contracture
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Ended recruitment
  2023-505625-14-00 7 2017-01-31 Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
• A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended recruitment
  2024-517321-99-00 4 2016-08-01 Myeloma multiplex
• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in … Ended recruitment
  2024-513521-23-00 5 2015-08-19 Prostate Cancer
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• KF2025#1 trial: Ketamine, cannabidiol and cobicistat interaction study Ended
  2025-523817-27-00 2 2026-03-05 Terveet vapaaehtoiset tutkittavat
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 4 2025-11-25 Alzheimer's Disease
• A Phase 3 study to assess the immune response and safety of rMenB+OMV NZ in primed healthy participants (10 to 20 years old) Ended
  2024-519549-31-00 5 2025-09-05 Invasive meningococcal disease (IMD)
• Accelerator-based BNCT for head and neck carcinoma Ended
  2024-515036-71-00 3 2025-04-15 Head and neck carcinoma
• A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML Ended
  2024-514356-33-00 7 2025-02-11 "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML),
• Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion Ended
  2022-502878-16-00 5 2025-01-23 Acute ischemic strokes with incomplete reperfusion
• A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 i … Ended
  2024-518088-37-01 3 2024-12-04 Melanoma, SCCHN
• KF2024#1 trial: Esketamine interaction study Ended
  2024-516892-34-00 2 2024-12-03 healthy volunteers
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

Showing 289–312 of 383 trials